Although the effects of IL-17B neutralization remain to be better defined, the possibility of remodeling the tumor immune microenvironment, in particularly by decreasing the immunosuppression linked to the strong infiltration by macrophages and neutrophils, is an interesting mechanism in the context of resistance to new immunotherapies, such as checkpoint inhibitors and immunogenic chemotherapies, or radiotherapy. The gene discussed is IL17B; the disease is neoplasm.